@article {951,
	title = {Synthesis and insulinomimetic activities of novel mono- and tetranuclear oxovanadium(IV) complexes with 3-hydroxypyridine-2-carboxylic acid},
	journal = {Journal of Inorganic Biochemistry},
	volume = {98},
	number = {1},
	year = {2004},
	note = {ISI Document Delivery No.: 760DETimes Cited: 24Cited Reference Count: 21},
	month = {Jan},
	pages = {105-112},
	type = {Article},
	abstract = {Two chargeless VO(IV) complexes with 3-hydroxypyridine-2-carboxylic acid (H(2)hpic), [VO(Hhpic-O,O)(Hhpic-O,N)(H2O)(.)3H(2)O (1) and the cyclic tetramer [(VO)4(mu-(hpic-O,O,N))(4)(H2O)(4)](.)8H(2)O (2), have been synthesized and characterized by elemental analysis, mass, infrared, electronic absorption, electron spin resonance (ESR) spectroscopies, and X-ray crystallography. Their coordination structures are similar to each other (and 1 is readily transformed into 2), but are quite different from that of bis(pyridine-2-carboxylato)oxovanadium(IV). The magnetic susceptibility of 2 indicates the presence of a weak ferromagnetic intramolecular interaction between the V atoms at low temperature, in addition to a weak antiferromagnetic intermolecular interaction. The ESR signal of 2 was broad, while I showed an eight-line hyperfine splitting pattern due to coupling of the impaired electron with the V-51 nucleus (I = 7/2). The ESR spectrum and cyclic voltammogram of 2 clearly show that the cyclic tetramer remains intact in solution. The insulinomimetic activity of 1 and 2 was evaluated by means of in vitro measurements of the inhibition of free fatty acid release from epinephrine-treated isolated rat adipocytes. While I exerted higher insulinomimetic activity than VOSO4, the activity of 2 was significantly lower than that of VOSO4. Hence 2 appears to retain its cyclic structure during the in vitro test. These results indicate that the rational ligand design for VO complexes might be a promising approach to obtain superior insulinomimetic activity. (C) 2003 Elsevier Inc. All rights reserved.},
	keywords = {BLOOD-GLUCOSE, cyclic tetranuclear complex, INDUCED DIABETIC RATS, insulinomimetic activity, oxovanadium, SOLID-STATE, VANADIUM(IV), VANADYL COMPLEX},
	isbn = {0162-0134},
	url = {<Go to ISI>://000187795700014},
	author = {Nakai, M. and Obata, M. and Sekiguchi, F. and Kato, M. and Shiro, M. and Ichimura, A. and Kinoshita, I. and Mikuriya, M. and Inohara, T. and Kawabe, K. and Sakurai, H. and Orvig, Chris and Yano, S.}
}
@article {4399,
	title = {Kinetic analysis and comparison of uptake, distribution, and excretion of V-48-labeled compounds in rats},
	journal = {Journal of Applied Physiology},
	volume = {84},
	number = {2},
	year = {1998},
	note = {ISI Document Delivery No.: YU964Times Cited: 63Cited Reference Count: 43},
	month = {Feb},
	pages = {569-575},
	type = {Article},
	abstract = {Vanadium has been found to be orally active in lowering plasma glucose levels; thus it provides a potential treatment for diabetes mellitus. Bis(maltolato)oxovanadium(rv) (BMOV) is a well-characterized organovanadium compound that has been shown in preliminary studies to have a potentially useful absorption profile. Tissue distributions of BMOV compared with those of vanadyl sulfate (VS) were studied in Wistar rats by using V-48 as a tracer. In this study, the compounds were administered in carrier-added forms by either oral gavage or intraperitoneal injection. Data analyzed by a compartmental model, by using simulation, analysis, and modeling (i.e., SAAM II) software, showed a pattern of increased tissue uptake with use of V-48-BMOV compared with (VS)-V-48. The highest V-48 concentrations at 24 h after gavage were in bone, followed by kidney and liver. Most ingested V-48 was eliminated unabsorbed by fecal excretion. On average, V-48 concentrations in bone, kidney, and liver 24 h after oral administration of V-48-BMOV were two to three times higher than those of (VS)-V-48, which is consistent with the increased glucose-lowering potency of BMOV in acute glucose lowering compared with VS.},
	keywords = {ADIPOCYTES, analysis, and modeling, BIS(MALTOLATO)OXOVANADIUM(IV), compartmental modeling, diabetes, DISSOCIATION, FERRIC MALTOL, GLUCOSE, INDUCED DIABETIC RATS, INSULIN, insulin mimetic, METABOLISM, MOLYBDENUM, SIMULATION, SMALL-INTESTINE, Software, VANADIUM, VANADYL SULFATE},
	isbn = {8750-7587},
	url = {<Go to ISI>://000071774300025},
	author = {Setyawati, I. A. and Thompson, K. H. and Yuen, V. G. and Sun, Y. and Battell, M. and Lyster, D. M. and Vo, C. and Ruth, T. J. and Zeisler, S. and McNeill, J. H. and Orvig, Chris}
}
@article {3578,
	title = {COMPARISON OF THE GLUCOSE-LOWERING PROPERTIES OF VANADYL SULFATE AND BIS(MALTOLATO)OXOVANADIUM(IV) FOLLOWING ACUTE AND CHRONIC ADMINISTRATION},
	journal = {Canadian Journal of Physiology and Pharmacology},
	volume = {73},
	number = {1},
	year = {1995},
	note = {ISI Document Delivery No.: QN264Times Cited: 71Cited Reference Count: 31},
	month = {Jan},
	pages = {55-64},
	type = {Article},
	abstract = {Numerous studies, bath in vitro and in vivo, have demonstrated the insulin-mimetic properties of vanadium. Chronic oral administration of inorganic and organic compounds of both vanadium(IV) and vanadium(V) reduced plasma glucose levels and restored plasma lipid levels in streptozotocin-diabetic rats. We investigated the acute effects of both vanadyl sulfate and bis(maltolato)oxovanadium(IV) (BMOV), an organic vanadium compound, on plasma glucose levels by several routes of administration. Previous studies have shown that chronic administration of vanadyl sulfate has resulted in a sustained euglycemia following withdrawal of the drug. This effect was not observed following the chronic administration of BMOV; therefore, we investigated the effect of increasing the concentration of BMOV on the production of a sustained euglycemic response. An acute plasma glucose lowering effect was obtained with both vanadyl sulfate and BMOV when administered as a single dose by either oral gavage or intraperitoneal injection. In those animals that responded to vanadium treatment, plasma glucose levels were within the normal range within 2 to 6 h when given by i.p. injection or within 4 to 8 h when given by oral gavage. BMOV-treated rats that responded to treatment maintained the euglycemic effect for extended periods, ranging from 1 to 14 weeks following administration. However, vanadyl sulfate treated rats reverted to hyperglycemia within 12 to 24 h, depending on the route of administration. Intravenous administration of BMOV was effective in lowering plasma glucose levels only when administered by continuous infusion. An oral dose - response curve showed that BMOV was 2 to 3 times as potent as vanadyl sulfate. This difference in potency was observed with both oral and intraperitoneal administration, which suggests that the increase in potency with BMOV cannot be totally attributed to increased gastrointestinal absorption. Organic chelation of vanadium may facilitate uptake into vanadium-sensitive tissues. Chronic oral administration of higher concentrations of BMOV did not result in a sustained reduction in plasma glucose following withdrawal of the drug. All diabetic rats eventually responded to increased concentrations of BMOV with a restoration of plasma glucose levels to normal values; however, reversion to the hyperglycemic state occurred within 2 days of withdrawal of treatment. Chronic oral administration of BMOV did not produce a sustained euglycemic effect following withdrawal, but acute administrations of the compound by either oral gavage or intraperitoneal injection did produce a long-term reduction in plasma glucose levels. Rats treated chronically with vanadyl sulfate remained euglycemic even after the drug was withdrawn. However, acute treatment produced only a transient euglycemia.},
	keywords = {ACUTE, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, DOSE RESPONSE, GAVAGE, HOMEOSTASIS, IMPROVEMENT, INDUCED DIABETIC RATS, INSULIN, STREPTOZOTOCIN DIABETIC, SULFATE, VANADYL},
	isbn = {0008-4212},
	url = {<Go to ISI>://A1995QN26400008},
	author = {Yuen, V. G. and Orvig, Chris and McNeill, J. H.}
}
